Altimmune (ALT) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Altimmune (ALT) is Neutral.

The composite score behind that read is -0.18, weighing +0.01 of bullish evidence against -0.37 bearish.

Altimmune last closed at $2.61, +0.38% on the session.

Against the IVW growth benchmark the position is -0.42% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

20 graded predictions for ALT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Altimmune in the 23rd percentile on return on equity, where 100 is best.

Altimmune is classified under Health Care / Biotechnology, with a market capitalisation of $505.75M.

StockMap tracks Altimmune as the 178th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Altimmune ranks 292nd of 381 in the group, against a group median of -0.08.